Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Landlady greets regular at real ale pub
Investing Articles

£20,000 in an ISA today can earn a second income by the summer!

Buying quality dividend shares is a proven tactic for building a chunky second income, with the money starting to flow…

Read more »

Wall Street sign in New York City
Investing Articles

The stock market’s fearful. Is it time to be greedy?

There is a palpable sense of fear stalking the stock market. Yet many share prices have held up fairly well…

Read more »

Investing Articles

Why on earth haven’t I bought dirt-cheap Barclays shares yet?

Harvey Jones is red hot for Barclays shares but he's also getting cold feet about buying them in the current…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

Meet the top 10 highest-dividend-yield stocks in the FTSE 250

In 2026, the UK’s flagship growth index offers a 3.4% dividend yield. But these 10 income stocks currently offer an…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Should I buy more FTSE 100 stocks or conserve my cash for even bigger bargains?

After a volatile week for the FTSE 100, Harvey Jones asks if we've reached the maximum point of opportunity. Or…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

£10,000 buys 11,764 shares of this REIT, unlocking £723.49 in passive income

UK REITs offer some of the largest dividend yields on the London Stock Exchange today. Zaven Boyrazian explores the passive…

Read more »

ISA Individual Savings Account
Investing Articles

How much do I need in a Stocks and Shares ISA to aim for a £900 monthly second income?

Hoping to unlock a chunky second income from a Stocks and Shares ISA? By investing a little each month, it…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

Oil surges. Stock markets fall. I’m looking to buy cheap stocks

It looks like volatility could soon enter the UK stock market. But this might prove an opportunity for investors to…

Read more »